Cowen Inc’s Supernus Pharmaceuticals SUPN Stock Holding History

Cowen Inc’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-13,000	Closed	-$560K	–	301
2017 Q2	$560K	Buy	+13,000	New	+$463K	0.03%	207
2015 Q4	–	Sell	-10,000	Closed	-$140K	–	334
2015 Q3	$140K	Sell	10,000 -20,000	-67%	-$372K	0.01%	221
2015 Q2	$509K	Buy	+30,000	New	+$427K	0.03%	235

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Cowen Inc's SUPN Position: Q3 2017 in Review

Cowen Inc sold out of Supernus Pharmaceuticals (SUPN) in Q3 2017, closing a stake of 13,000 shares — an estimated $560K sold.

Cowen Inc first reported a position in SUPN in Q2 2015 and held it in 3 quarters. The position peaked at $560K in Q2 2017. 275 funds tracked by Wall St. Rank hold SUPN as of Q3 2017.

Cowen Inc reported no remaining Supernus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Cowen Inc sold 13,000 Supernus Pharmaceuticals shares in Q3 2017, an estimated $560K.
Cowen Inc first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 3 quarters.
Cowen Inc's Supernus Pharmaceuticals position peaked at $560K in Q2 2017.
275 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2017.

Based on Cowen Inc's 13F filing for Q3 2017, filed 14 Nov 2017.